Publications
- Voigt E, Quelle DE.Int J Mol Sci. 2023 Sep 2;24(17):13596. FOXM1, MEK, and CDK4/6: New Targets for Malignant Peripheral Nerve Sheath Tumor Therapy. doi: 10.3390/ijms241713596.
- Kohlmeyer JL, Lingo JJ, Kaemmer CA, Scherer A, Warrier A, Voigt E, Raygoza Garay JA, McGivney GR, Brockman QR, Tang A, Calizo A, Pollard K, Zhang X, Hirbe AC, Pratilas CA, Leidinger M, Breheny P, Chimenti MS, Sieren JC, Monga V, Tanas MR, Meyerholz DK, Darbro BW, Dodd RD, Quelle DE. CDK4/6-MEK inhibition in MPNSTs causes plasma cell infiltration, sensitization to PD-L1 blockade, and tumor regression. Clin Cancer Res. 2023 Jul 6:CCR-23-0749. doi: 10.1158/1078-0432.CCR-23-0749. Online ahead of print. PMID: 37410426
- Gutierrez WR, Scherer A, Rytlewski JD, Laverty EA, Sheehan AP, McGivney GR, Brockman QR, Knepper-Adrian V, Roughton GA, Quelle DE, Gordon DJ, Monga V, Dodd RD. Augmenting chemotherapy with low-dose decitabine through an immune-independent mechanism. JCI Insight. 2022 Nov 22;7(22):e159419. doi: 10.1172/jci.insight.159419. PMID: 36227698
- Kohlmeyer JL, Kaemmer CA, Lingo JJ, Voigt E, Leidinger MR, McGivney GR, Scherer A, Koppenhafer SL, Gordon DJ, Breheny P, Meyerholz DK, Tanas MR, Dodd RD, Quelle DE. Oncogenic RABL6A promotes NF1-associated MPNST progression in vivo. Neurooncol Adv. 2022 Apr 9;4(1):vdac047. doi: 10.1093/noajnl/vdac047. eCollection 2022 Jan-Dec. PMID: 35571990
- RABL6A promotes pancreatic neuroendocrine tumor angiogenesis and progression in vivo.
Maharjan CK, Umesalma S, Kaemmer CA, Muniz VP, Bauchle C, Mott SL, Zamba KD, Breheny P, Leidinger MR, Darbro BW, Stephens SB, Meyerholz DK, and Quelle DE: Biomedicines 9(2):633, 2021. https://doi.org/10.3390/biomedicines9060633. PMCID: PMC8228095 - Development and comparison of novel bioluminescent mouse models of pancreatic neuroendocrine neoplasm metastasis.
Kaemmer CA, Umesalma S, Maharjan CK, Moose DL, Narla G, Mott SL, Zamba GKD, Breheny P, Darbro BW, Bellizzi AM, Henry MD, and Quelle DE: Sci Rep 11(1):10252, 2021. https://doi.org/10.1038/s41598-021-89866-1. PMCID: PMC8119958 - Combination therapies for MPNSTs targeting RABL6A-RB1 signaling.
Kohlmeyer JL, Gordon DJ, Tanas MR, Dodd RD, Monga V, Darbro BW, and Quelle DE: Combination therapies for MPNSTs targeting RABL6A-RB1 signaling. Oncotarget 12(1):10-14, 2021. https://doi.org/10.18632/oncotarget.27862. PMCID: PMC7800773 - Gene Expression signatures identify novel therapeutics for metastatic pancreatic neuroendocrine tumors.
Scott AT, Weitz M, Breheny PJ, Ear PH, Darbro B, Brown BJ, Braun TA, Li G, Umesalma S, Kaemmer CA, Maharjan CK, Quelle DE, Bellizzi AM, Chandrasekharan C, Dillon JS, O’Dorisio TM, and Howe JR. Clin Cancer Res 26(8):2011-2021, 2020. https://doi.org/10.1158/1078-0432.ccr-19-2884. PMCID: PMC7165057 - RABL6A is an essential driver of MPNSTs that negatively regulates the RB1 pathway and sensitizes tumor cells to CDK4/6 inhibitors.
Kohlmeyer JL, Kaemmer CA, Pulliam C, Maharjan CK, Moreno Samayoa A, Major H, Cornick K, Knepper-Adrian V, Khanna R, Sieren JC, Leidinger MR, Meyerholz DK, Zamba G, Weimer JM, Dodd RD, Darbro BW, Tanas MR, and Quelle DE. Clin Cancer Res 26(12):2997-3011, 2020. https://doi.org/10.1158/1078-0432.ccr-19-2706. PMCID: PMC7299809 - RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth.
Umesalma S, Kaemmer CA, Kohlmeyer JL, Letney B, Schab AM, Reilly JA, Sheehy RM, Hagen J, Tiwari N, Zhan F, Leidinger MR, O'Dorisio TM, Dillon J, Merrill RA, Meyerholz DK, Perl AL, Brown BJ, Braun TA, Scott AT, Ginader T, Taghiyev AF, Zamba GK, Howe JR, Strack S, Bellizzi AM, Narla G, Darbro BW, Quelle FW, Quelle DE. J Clin Invest. 2019 Mar 4;130. pii: 123049. doi: 10.1172/JCI123049. eCollection 2019 Mar 4. PMID: 30721156 - A porcine model of neurofibromatosis type 1 that mimics the human disease.
White KA, Swier VJ, Cain JT, Kohlmeyer JL, Meyerholz DK, Tanas MR, Uthoff J, Hammond E, Li H, Rohret FA, Goeken A, Chan CH, Leidinger MR, Umesalma S, Wallace MR, Dodd RD, Panzer K, Tang AH, Darbro BW, Moutal A, Cai S, Li W, Bellampalli SS, Khanna R, Rogers CS, Sieren JC, Quelle DE, Weimer JM. JCI Insight. 2018 Jun 21;3(12). pii: 120402. doi: 10.1172/jci.insight.120402. eCollection 2018 Jun 21. PMID: 29925695 - Immunohistochemical Markers for Prospective Studies in Neurofibromatosis-1 Porcine Models.
Meyerholz DK, Ofori-Amanfo GK, Leidinger MR, Goeken JA, Khanna R, Sieren JC, Darbro BW, Quelle DE, Weimer JM. J Histochem Cytochem. 2017 Oct;65(10):607-618. doi: 10.1369/0022155417729357. Epub 2017 Aug 28. PMID: 28846462 - Myst2/Kat7 histone acetyltransferase interaction proteomics reveals tumour-suppressor Niam as a novel binding partner in embryonic stem cells.
Pardo M, Yu L, Shen S, Tate P, Bode D, Letney BL, Quelle DE, Skarnes W, Choudhary JS. Sci Rep. 2017 Aug 15;7(1):8157. doi: 10.1038/s41598-017-08456-2. PMID: 28811661 - p53 Acetylation: Regulation and Consequences.
Reed SM, Quelle DE. Cancers (Basel). 2014 Dec 23;7(1):30-69. doi: 10.3390/cancers7010030. Review. PMID: 25545885 - NIAM-deficient mice are predisposed to the development of proliferative lesions including B-cell lymphomas.
Reed SM, Hagen J, Muniz VP, Rosean TR, Borcherding N, Sciegienka S, Goeken JA, Naumann PW, Zhang W, Tompkins VS, Janz S, Meyerholz DK, Quelle DE. PLoS One. 2014 Nov 13;9(11):e112126. doi: 10.1371/journal.pone.0112126. eCollection 2014. PMID: 25393878 - RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent manner.
Hagen J, Muniz VP, Falls KC, Reed SM, Taghiyev AF, Quelle FW, Gourronc FA, Klingelhutz AJ, Major HJ, Askeland RW, Sherman SK, O'Dorisio TM, Bellizzi AM, Howe JR, Darbro BW, Quelle DE. Cancer Res. 2014 Nov 15;74(22):6661-70. doi: 10.1158/0008-5472.CAN-13-3742. Epub 2014 Oct 1. PMID: 25273089 - Development and translational imaging of a TP53 porcine tumorigenesis model.
Sieren JC, Meyerholz DK, Wang XJ, Davis BT, Newell JD Jr, Hammond E, Rohret JA, Rohret FA, Struzynski JT, Goeken JA, Naumann PW, Leidinger MR, Taghiyev A, Van Rheeden R, Hagen J, Darbro BW, Quelle DE, Rogers CS. J Clin Invest. 2014 Sep;124(9):4052-66. doi: 10.1172/JCI75447. Epub 2014 Aug 8. PMID: 25105366 - ARF sees Pdgfrβ through the miR.
Reed SM, Quelle FW, Quelle DE. Cell Cycle. 2014;13(10):1520-1. doi: 10.4161/cc.28900. Epub 2014 Apr 22. PMID: 24755551 - Nuclear interactor of ARF and Mdm2 regulates multiple pathways to activate p53.
Reed SM, Hagen J, Tompkins VS, Thies K, Quelle FW, Quelle DE. Cell Cycle. 2014;13(8):1288-98. doi: 10.4161/cc.28202. Epub 2014 Feb 19. PMID: 24621507 - RABL6A, a novel RAB-like protein, controls centrosome amplification and chromosome instability in primary fibroblasts.
Zhang X, Hagen J, Muniz VP, Smith T, Coombs GS, Eischen CM, Mackie DI, Roman DL, Van Rheeden R, Darbro B, Tompkins VS, Quelle DE. PLoS One. 2013 Nov 25;8(11):e80228. doi: 10.1371/journal.pone.0080228. eCollection 2013. PMID: 24282525 - RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients.
Muniz VP, Askeland RW, Zhang X, Reed SM, Tompkins VS, Hagen J, McDowell BD, Button A, Smith BJ, Weydert JA, Mezhir JJ, Quelle DE. Genes Cancer. 2013 Jul;4(7-8):273-84. doi: 10.1177/1947601913501074. PMID: 24167655 - The ARF tumor suppressor inhibits tumor cell colonization independent of p53 in a novel mouse model of pancreatic ductal adenocarcinoma metastasis.
Muniz VP, Barnes JM, Paliwal S, Zhang X, Tang X, Chen S, Zamba KD, Cullen JJ, Meyerholz DK, Meyers S, Davis JN, Grossman SR, Henry MD, Quelle DE. Mol Cancer Res. 2011 Jul;9(7):867-77. doi: 10.1158/1541-7786.MCR-10-0475. Epub 2011 Jun 2. PMID: 21636682 - Residues in the alternative reading frame tumor suppressor that influence its stability and p53-independent activities.
di Tommaso A, Hagen J, Tompkins V, Muniz V, Dudakovic A, Kitzis A, Ladeveze V, Quelle DE. Exp Cell Res. 2009 Apr 15;315(7):1326-35. doi: 10.1016/j.yexcr.2009.01.010. Epub 2009 Jan 27. PMID: 19331830